Rosacea: Pathophysiology, Clinical Features, and Treatment
August 1, 2016 21 minutes read
AUTHORS
Dawnielle Endly, DO, Dermatology Resident, Nova Southeastern University College of Osteopathic Medicine/Largo Medical Center, Largo, FL
Ali Zaidi, DO, Intern, Manatee Memorial Hospital, Bradenton, FL
Jessica Perkins, DO, Dermatology Resident, Nova Southeastern University College of Osteopathic Medicine/Largo Medical Center, Largo, FL
Richard A. Miller, DO, Program Director, Dermatology Residency Program, Nova Southeastern University College of Osteopathic Medicine/Largo Medical Center, Largo, FL
PEER REVIEWER
Glen D. Solomon, MD, FACP, Professor and Chair, Department of Internal Medicine, Wright State University, Boonshoft School of Medicine, Dayton, OH
To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, Dr. Wise (editor) reports he is on the speakers bureau for the Medicines Company. Dr. Endly, (author), Dr. Zaidi (author), Dr. Perkins (author), Dr. Miller (author), Dr. Solomon (peer reviewer), Ms. Coplin (executive editor), and Ms. Mark (executive editor) report no financial relationships relevant to this field of study.
A common chronic skin condition that affects adults, rosacea is characterized by a wide spectrum of signs and symptoms. Patients classically experience facial flushing and erythema, telangiectasias, facial swelling, papules, and pustules involving the convexities of centrofacial areas such as the cheeks, nose, chin, and forehead. A key diagnostic finding is diffuse background erythema of these areas that worsens during a flare.1,2 A flare is often referred to as flushing and results from sudden vasodilation of superficial blood vessels in the skin.2,3 Because of the variety of potential rosacea presentations, the National Rosacea Society assembled a committee of rosacea experts to establish a subtype classification system to aid in diagnosis and appropriate treatment.4 The National Rosacea Society’s consensus committee described four subtypes and one variant, all of which can range in severity from mild to moderate to severe. (See Table 1.)
Table 1. Subtypes and Variants of Rosacea and Their Major Characteristics4 |
|
|
Subtype |
Characteristics |
|
Erythematotelangiectatic |
Persistent central facial erythema with flushing ± telangiectasia |
|
Papulopustular |
Transient papules and pustules overlying persistent central facial erythema |
|
Phymatous |
Prominent pores with thickened, nodular areas of enlargement, most commonly affects the nose |
|
Ocular |
Conjunctivitis, periorbital edema, blepharitis, chalazia, and hordeola on exam with complaints of foreign body sensation, burning, or stinging |
|
Variant |
|
|
Granulomatous |
Hard brown, yellow, or red monomorphic papules or nodules |
Rosacea is most often seen in Caucasians or individuals with lighter skin types and is rarely seen in African Americans. Reports of rosacea prevalence vary from 1.34% to 22%, but these results are confounded by numerous differences and shortcomings in study designs.5-9 The typical age of onset is between 30 and 50 years of age, but the condition can present earlier or later in life as well. The underlying cause of rosacea is poorly defined with many remaining unknowns. Several of the suspected contributing factors include genetic factors, an aberrant innate immune response, vascular hypersensitivity, ultraviolet radiation, microorganisms, and skin barrier dysfunction.
Pathophysiology
Genetic Factors
A patient’s particular genes may contribute to his or her development of rosacea as an adult. Of those with rosacea, 10-20% report a family history of rosacea.10 The higher incidence of rosacea in those of Celtic or Northern European descent also suggests a possible genetic component. Still, several genomic studies have failed to pinpoint a causative gene.11
Innate Immune Response
The innate immune system serves as the body’s nonspecific, acute defense mechanism against infections and other environmental stimuli. When triggered, it leads to the controlled release of numerous cytokines and antimicrobial peptides in the skin. The innate immune system seems to be disrupted in patients who have rosacea.
In 2007, Yamasaki et al illustrated that facial skin from patients with rosacea displays unusually elevated levels of an antimicrobial peptide called cathelicidin as well as cathelicidin’s processing enzyme, a serine protease called kallikrein 5.12 Kallikrein 5 cleaves cathelicidin into a smaller, active peptide called LL-37. In addition to being more abundant, the LL-37 found in those with rosacea is smaller than in those unaffected by rosacea. These mutant forms of LL-37 are able to upregulate the innate immune system with resultant inflammation and angiogenesis.13 Yamasaki et al further demonstrated this concept with a study that involved the injection of cathelicidin peptides from rosacea patients into murine skin that led to inflammation and vasodilation.14,15
Vascular Hypersensitivity
Persistent background centrofacial erythema and telangiectasias remain a key diagnostic clue to the diagnosis of rosacea. An acute, transient worsening of facial erythema, known as flushing, can occur after exposure to various triggers.16 (See Table 2.) Flushing occurs when a trigger results in an exaggerated vasodilation response by cutaneous vasculature. For example, compared to controls, patients with rosacea were found to flush more readily after heat exposure.17 Other possible triggers include spicy foods or alcohol, but the exact mechanism of how these dietary factors play a role in the pathogenesis has yet to be elucidated. Various medications, such as amiodarone, topical steroids, nasal steroids, and high doses of vitamins B6 or B12, are other less frequently described potential rosacea triggers.18,19 One study found the endothelial cells lining blood vessels and lymphatics in those with rosacea express higher levels of vascular endothelial growth factor (VEGF), CD31 (an endothelial cell marker), and D2-40 (a lymphatic endothelial marker).20 This knowledge further supports the idea of vascular hypersensitivity and excessive endothelial stimulation of cutaneous vasculature in those with rosacea.
Table 2. Potential Triggers for Facial Flushing and Worsening of Rosacea 16,19 |
|
|
Rosacea Triggers |
Patients Affected |
|
Sun exposure |
81% |
|
Stress |
79% |
|
Heat |
75% |
|
Wind |
57% |
|
Strenous activity |
56% |
|
Alcohol consumption |
52% |
|
Cold weather |
46% |
|
Spicy foods |
45% |
|
Certain skin care products |
41% |
|
Hot beverages |
36% |
|
Medications |
15% |
|
SOURCE: Author adapted. |
|
Ultraviolet Radiation
Ultraviolet (UV) exposure and photodamage have been proven to play an important role in the pathophysiology of rosacea. Most patients with rosacea, regardless of subtype, report worsening of their rosacea along with flushing after being out in the sun. Additionally, the clinical findings of rosacea are most prominent on areas that suffer the highest levels of UV exposure (i.e., protuberant or convex areas of the face). UVA radiation increases the expression of matrix metalloproteinases (MMPs) and denatured collagen in the skin.21 MMPs are zinc-containing proteases that break down various components of the extracellular matrix, resulting in damage to blood vessels and the dermal matrix. Exposure to UVB radiation leads to the production of VEGF and other angiogenic factors from keratinocytes, further contributing to the hypervascularity seen in those with rosacea.22 In general, UV radiation generates reactive oxygen species (ROS), which have a pro-inflammatory effect on the skin. ROS bind to toll-like receptor 2 (TLR2) on keratinocytes, which only further propagates the inflammatory cascade occurring in rosacea.15 The epidermis in those with rosacea expresses higher amounts of both ROS and TLR2 than in those without rosacea.23,24
Microorganisms
Demodex mites are a normal commensal organism found within the pilosebaceous units of facial skin. However, many studies have found a higher density of mites on the skin of patients with rosacea when compared to unaffected individuals.25 It is unclear whether these mites are a possible trigger for rosacea or rather a response to the numerous changes in the skin’s microenvironment. Regardless, several studies suggest they play some role in the multifactorial pathophysiology that drives rosacea.
When mites are numerous and infest a pilosebaceous unit, an intense peri-follicular infiltrate of mainly CD4+ helper T-cells can be seen on histology.26 Demodex mites also contain the bacterial organism Bacillus oleronius, which also may play a pro-inflammatory role. One study closely examined antigenic proteins from the B. oleronius bacterium and revealed these proteins have the potential to stimulate an inflammatory response in patients with rosacea.27 The mites also release chitin, which can activate TLR2 on keratinocytes.28 Thus, Demodex mites and B. oleronius both appear to contribute to the dysregulation of the local innate immune response seen in rosacea.
Skin Barrier Dysfunction
A majority of patients with rosacea complain of “sensitive skin” and report dry facial skin with a stinging or burning sensation. As discussed earlier, serine protease levels are elevated in those with rosacea, and this may result in epidermal barrier dysfunction. A stinging or burning sensation results when a sensory irritant, such as lactic acid for example, easily penetrates the skin through a disruption or abnormality in the epidermal barrier.29 Individuals with rosacea also have been found to have increased transepidermal water loss resulting in dry, sensitive skin.3
Clinical Features
The primary clinical features of rosacea most often involve the convexities of the central face and include non-transient background erythema, flushing (transient erythema), papules, pustules, and telangiectasias. Additionally, numerous secondary signs and symptoms may accompany the primary clinical features above. Some of the secondary features of rosacea include dry skin with a burning or stinging sensation, elevated red inflammatory plaques, facial edema, ocular manifestations, and phymatous changes.
Rosacea has a wide variety of clinical presentations and can exhibit different combinations of the above-described clinical features. Thus, the National Rosacea Society formed a committee to design a standard classification system for rosacea and described four subtypes of rosacea and one variant.4 The classification system resulted in a standard terminology to allow precise diagnosis and treatment of all subtypes of rosacea. The four subtypes and one variant are described in further detail below and summarized in Table 1. All subtypes typically begin mild and can progress to moderate or severe if untreated.
Erythematotelangiectatic Rosacea
Patients with this subtype mainly are characterized by a background of persistent facial erythema, frequent episodes of flushing, and telangiectasias. (See Figure 1.) Some of the more common secondary findings include central facial edema and dry skin with a stinging or burning sensation. These patients are typically fair-skinned and, thus, many clinicians find it challenging to differentiate erythematotelangiectatic rosacea in these individuals from chronic actinic damage, also known as dermatoheliosis. Dermatoheliosis even may exhibit flushing with temperature changes. However, patients with dermatoheliosis usually present later in life, have evidence or history of precancer or non-melanoma skin cancers, and do not display facial edema or complain of a stinging or burning sensation.
Figure 1. Erythematotelangiectatic Subtype of Rosacea |
 |
|
Image used with permission from VisualDx |
Papulopustular Rosacea
The key clinical feature of papulopustular rosacea is a temporary eruption of several small, dome-shaped, erythematous papules overlying persistent centrofacial erythema. (See Figure 2.) The papules may appear in crops or can be solitary and a pustule may surmount some. Typically, the papules resolve after about two weeks with no resultant scarring. These features should not be confused with those of seborrheic dermatitis or acne vulgaris. Seborrheic dermatitis typically presents with erythematous patches and a greasy, yellow scale involving the centrofacial creases (i.e., nasolabial folds) and eyebrows. This is in comparison to rosacea’s involvement of the convexities (protuberant areas), not the folds, of the central face. Papulopustular rosacea is commonly mistaken for acne vulgaris in younger patients, but can be differentiated by its lack of comedones, also known as whiteheads and blackheads.
Figure 2. Papulopustular Subtype of Rosacea |
 |
|
Image used with permission from Dr. Jere Mammino |
Phymatous Rosacea
Phymatous rosacea arises from hypertrophy of the sebaceous glands and thickening of the skin that results in nodules and enlargement of the affected area. The earliest clinical indication of phymatous rosacea is dilated pores, or patulous follicles. As the disease progresses, the hypertrophy of the tissue creates distortion of the affected areas with soft, nodular growths. Rhinophyma, or thickening of the nose, is the most common type of phymatous rosacea and predominantly occurs in males.30 (See Figure 3.) Rarely, phymatous rosacea may occur in other locations such as the central chin, central forehead, lower ears or earlobes, and eyelids as outlined in Table 3.4,10 Phymatous rosacea rarely may occur in other locations, such as the central chin (gnathophyma), central forehead (mentophyma), lower ears or earlobes (otophyma), and eyelids (blepharophyma).4,10 Phymatous rosacea is commonly misperceived as end-stage rosacea; however, many patients have mild or no preceding rosacea.10
Figure 3. Rhinophyma Seen in Phymatous Subtype of Rosacea |
 |
|
Image used with permission from Dr. Jere Mammino |
Table 3. Various Types of Phymatous Rosacea 10 |
|
|
Phyma |
Clinical Characteristics |
|
Rhinophyma |
Early on: dilated, patulous follicles most prominent at distal nose Later on: enlarged, nodular, deformed nose that often leads to debilitation and psychological implications for the patient |
|
Gnathophyma |
Rare occurrence that results in enlargement of the central chin |
|
Otophyma |
Hypertrophy of the dermis and adnexal structures of the lower half of the helices and earlobes |
|
Mentophyma |
Presents as a firm, swollen plaque that is cushion-like on the central forehead |
|
Blepharophyma |
Thickening and edema of the eyelids; this finding is not limited to phymatous rosacea, as it may be seen in severe papulopustular or ocular rosacea as well |
|
SOURCE: Author adapted. |
|
Ocular Rosacea
The clinical features of ocular rosacea are varied and nonspecific. Some of the nonspecific ocular complaints that patients may report include itching, tearing, dry eyes, a gritty sensation, blurred vision, and frequent styes. On exam, the patient’s eyes typically appear watery and may display conjunctival injection, tiny concretions in the eyelashes referred to as conical dandruff, and eyelid erythema. (See Figure 4.) Some patients suffer from a recurrent chalazion, a non-infectious cyst involving the meibomian glands, or hordeolum, a chronic staphylococcal infection of the zeis or meibomian glands. Up to 20% of patients with ocular rosacea have no accompanying cutaneous findings of rosacea and, thus, arriving at a diagnosis with certainty is very challenging in these cases.31 More commonly, ocular rosacea is seen in patients who also have one of the other subtypes of rosacea.
Figure 4. Mild Ocular Rosacea |
 |
|
Image used with permission from VisualDx |
Granulomatous Rosacea
Granulomatous rosacea is considered a clinical variant of rosacea rather than a specific subtype. The key clinical feature is hard, skin-colored, yellow, brown, or red papules or nodules that typically arise on the cheeks or periorificial skin. These bumps do not seem to be inflammatory in comparison to the papules and pustules seen in papulopustular rosacea. They are also monomorphic in each affected patient and overlay normal-appearing skin. Granulomatous rosacea typically does not coexist with any of the subtypes of rosacea. A biopsy of the affected area reveals granulomas with central necrosis and, thus, requires the clinician to perform further studies to rule out sarcoidosis and tuberculosis.32
Treatment Options
Due to the multifactorial pathophysiology and numerous subtypes of rosacea, management spans a wide spectrum of treatment modalities. In general, a thorough history should be taken to evaluate for all possible exacerbating factors. The patient then should be counseled on the importance of avoidance or moderation of the identified triggers.
General Skin Care Recommendations
Rosacea patients are encouraged to cleanse their faces twice daily with lukewarm water and a soap-free, pH-balanced cleanser. The cleanser should not have any scrubbing particles or harsh antibacterial agents. Then, they should apply a fragrance-free moisturizer to help combat the excessive dryness and increased transepidermal water loss.29 There are numerous over-the-counter topical cosmeceutical creams that are rich in antioxidants and may decrease the amount of reactive oxygen species in the skin contributing to rosacea.33 Although in general, heat can still induce a flare, regular photoprotection is key to reduce the possibility that UV exposure will trigger a rosacea flare.34 Although no specific sunscreen agent has been proven to be superior for those with rosacea, the general recommendation is to apply sun-blocking agents that contain titanium dioxide or zinc oxide with a sun protection factor of 30 or higher.
Categorizing patients by their subtype of rosacea is especially useful when specific treatment options are being considered. Patients then can be classified further according to their disease severity. This also can help the clinician to determine the most appropriate treatment regimen. The best treatment options for each subtype of rosacea are discussed below and summarized in Table 4.
Table 4. Treatment Options for Rosacea According to Subtype10 |
|
|
Erythematotelangiectatic Rosacea |
|
|
Treatment |
Comments |
|
General skin care recommendations |
Especially helpful, as this subtype is prone to “sensitivity” |
|
Photoprotection |
UV radiation potentiates dermal matrix damage |
|
Topical brimonidine (alpha-agonist) |
Results in vasoconstriction to temporarily improve erythema |
|
Laser therapy |
Pulsed dye and KTP improve telangiectasias |
|
Papulopustular Rosacea |
|
|
Treatment |
Comments |
|
Metronidazole cream or gel |
Can be used to clear inflammatory lesions or as an indefinite maintenance therapy |
|
Azeleic acid gel |
More effective than metronidazole ± more irritation |
|
Sodium sulfacetamide and sulfur lotion |
|
|
Erythromycin solution |
Solution is alcohol-based and poorly tolerated |
|
Clindamycin lotion |
|
|
Benzoyl peroxide and clindamycin |
May cause skin irritation |
|
Tretinoin cream or gel |
May improve associated photodamage; some poorly tolerate it |
|
Permethrin cream |
As effective as metronidazole for papules |
|
Systemic Treatments |
Comments |
|
Antimicrobial doxycycline |
100 mg once to twice daily for 4-12 weeks |
|
Sub-antimicrobial doxycycline |
40 mg daily (30 mg immediate release, 10 mg delayed release) |
|
Minocycline |
100 mg twice daily for 4-12 weeks |
|
Azithromycin |
250-500 mg three times a week for flares or maintenance |
|
Isotretinoin |
10-40 mg daily |
|
SOURCE: Author adapted. |
|
Table 4. Treatment Options for Rosacea According to Subtype (Continued) 10 |
|
|
Phymatous Rosacea |
|
|
Treatment |
Comments |
|
Isotretinoin |
May reduce nasal volume and halt progression |
|
Surgical excision |
Can effectively debulk and resculpt the nose |
|
Other surgical modalities |
Electrosurgery, dermabrasion, and CO2 laser |
|
Ocular Rosacea |
|
|
Treatment |
Comments |
|
Eyelid hygiene and artificial tears |
Frequently effective for mild disease |
|
Fusidic acid drops |
Useful after oral antibiotics to maintain remission |
|
Metronidazole gel |
Same as above |
|
Systemic antibiotics per above |
Treats moderate to severe disease |
|
SOURCE: Author adapted. |
|
Erythematotelangiectatic Rosacea
Patients with mild erythematotelangiectatic rosacea have mild fixed facial erythema and intermittent flushing, but no telangiectasias. Treatment for these patients typically focuses on the general skin care recommendations discussed previously. As disease severity progresses to moderate and severe, patients begin to have more frequent flushing and several telangiectasias. If the patient expresses concern about the centrofacial erythema, a topical alpha-adrenergic receptor agonist (such as brimonidine) may be applied to the entire face in the morning. This typically results in direct vasoconstriction within one hour of application and a visible reduction in facial erythema.35 Telangiectasias require the use of lasers such as pulsed dye and potassium-titanyl-phosphate lasers.36 Metronidazole, a common topical antibacterial agent used to treat rosacea, has been found to be ineffective in the treatment of erythematotelangiectatic rosacea and often causes irritation in patients with this subtype.37
Papulopustular Rosacea
Topical and systemic antibiotics are the mainstay of treatment for papulopustular rosacea. Systemic antibiotics, such as doxycycline, typically are used to treat papulopustular flares. They are prescribed in short courses, typically four to six weeks, as opposed to longer regimens of up to six months when used for acne. Patients who suffer from moderate or severe papulopustular rosacea may require frequent courses of oral antibiotics.
After successful treatment of a flare, patients are encouraged to continue treatment with topical antibiotics for maintenance therapy. In a large Cochrane review, metronidazole gel or cream and azelaic acid gel were the only topical treatments shown to effectively minimize papulopustular rosacea relapses.37 A more recent trend in the treatment of rosacea uses sub-antimicrobial doses of doxycycline. Sub-antimicrobial doses have anti-inflammatory effects and may be efficacious for all severities of papulopustular rosacea.38 This dosing regimen of doxycycline offers the advantages of once daily dosing and avoidance of antibiotic resistance, and doxycycline is the only FDA-approved oral treatment for papulopustular rosacea.36
Phymatous Rosacea
Mild phymatous rosacea typically presents with dilated pores and a small amount of hypertrophy. In 2010, Gollnick et al conducted a study that demonstrated oral isotretinoin as an efficacious and well-tolerated treatment option for mild phymatous rosacea.39 Moderate-to-severe phymatous rosacea demonstrates even further hypertrophy with distortion of the normal contour and, thus, requires surgery.10 Various surgical methods include complete surgical excision or incomplete excision via dermabrasion, electrosurgery, or CO2 laser ablation. These surgical modalities remove the hypertrophied sebaceous glands and connective tissue with minimal complications and satisfactory cosmetic results.40
Ocular Rosacea
People who suffer from mild ocular rosacea have minimal clinical findings, but complain of a dry, gritty sensation in the eyes. Cleansing the eyelid margins with a mild shampoo and using artificial tear replacement appears to be adequate for mild ocular disease.10 As severity increases, patients begin to develop conjunctivitis, crusting of the eyelids, and complain of burning, stinging, blurred vision, and chalazion or hordeolum. Moderate-to-severe ocular rosacea often requires topical and systemic antibiotics as outlined above for papulopustular rosacea.
Conclusion
Rosacea is a chronic inflammatory skin condition that primarily affects the protuberant areas of the central face. Patients often experience exacerbations and remissions of various clinical features such as facial flushing, erythema, telangiectasias, edema, papules, pustules, ocular lesions, and phymatous changes. Each patient with rosacea has a unique presentation, but most patients fit into one or more of the four subtypes (erythematotelangiectatic, papulopustular, phymatous, and ocular). The exact pathophysiology of rosacea remains unknown. However, various factors, such as genetics, innate immune system, vascular hypersensitivity, ultraviolet radiation, microorganisms, and skin barrier dysfunctions, all are proposed to play some role. All patients with rosacea should follow a gentle skin care regimen. The most common prescription treatments involve topical or systemic antibiotics. Ultimately, it is important to be able to distinguish rosacea from other cutaneous diseases, such as acne vulgaris, chronic actinic damage, or seborrheic dermatitis, to ensure successful treatment. One should not hesitate to refer a challenging or recalcitrant case to dermatology to rule out other possible less common dermatologic conditions.
REFERENCES
- Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004;51:327-341.
- Del Rosso JQ, Gallo RL, Tanghetti E, et al. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis 2013;91:1-8.
- Del Rosso JQ. Advances in understanding and managing rosacea: Part 1: Connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol 2012;5:16-25.
- Wilkin J, Dahl M, Detmar M, et al. Standard classification system of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002;46:584-587.
- Romanowicz M, Stephenson JJ, Del Rosso JQ, et al. Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol 2008;7:41-49.
- McAleer MA, Fitzpatrick P, Powell FC. Papulopustular rosacea: Prevalence and relationship to photodamage. J Am Acad Dermatol 2010;63:33-39.
- Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol 1989;69:419-423.
- Abram K, Silm H, Oona M. Prevalence of rosacea in an Estonian working population using a standard classification. Acta Derm Venereol 2010;90:269-273.
- Tan J, Schofer H, Araviiskaia E, et al. Prevalence of rosacea in the general population of Germany and Russia — The RISE study. J Eur Acad Dermatol Venereol 2016;30:428-434.
- Powell FC, Raghallaigh SN. Rosacea and Related Disorders. In: Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology 3rd ed. St. Louis: Elsevier Saunders; 2012:561-569.
- Two AM, Wu W, Gallo RL, et al. Rosacea. Part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol 2015;72:749-758.
- Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007;13:975.
- Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003;111:1665-1672.
- Yamasaki K, Schauber J, Coda A, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006;20:2068-2080.
- Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci 2009;55:77-81.
- Cohen AF, Tiemstra JD. Diagnosis and treatment of rosacea. J Am Board Fam Pract 2002;15:214-217.
- Guzman-Sanchez DA, Ishiuji Y, Patel T, et al. Enhanced blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol 2007;57:800-805.
- Jansen T, Romiti R, Kreuter A, et al. Rosacea fulminans triggered by high-dose vitamins B6 and B12. J Eur Acad Dermatol Venereol 2001;15:484-485.
- Chauhan N, Ellis D. Rosacea: Pathophysiology and management principles. Facial Plast Surg Clin North Am 2013;21:127-136.
- Gomaa AH, Yaar M, Eyada MM, et al. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol 2007;34:748-753.
- Naru E, Suzuki T, Moriyama M, et al. Functional changes induced by chronic UVA radiation to cultured human dermal fibroblasts. Br J Dermatol 2005;153:6-12.
- Yano K, Kadoya K, Kajiya K, et al. UVB irradiation of human skin induces an angiogenic switch that is mediated by upregulation of VEGF and by downregulation of thrombospondin-1. Br J Dermatol 2005;152:115-121.
- Jones D. Reactive oxygen species and rosacea. Cutis 2004;74:17-20, 32-34.
- Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 2011;131:688-697.
- Zhao YE, Wu LP, Peng Y, et al. Retrospective analysis of the association between Demodex infestation and rosacea. Arch Dermatol 2010;146:896-902.
- Georgala S, Katoulis AC, Kylafis GD, et al. Increased density of Demodex folliculorum and evidence of delayed hypersensitivity reaction in subjects with papulopustular rosacea. J Eur Acad Dermatol Venereol 2001;15:441-444.
- Lacey N, Delaney S, Kavanagh K, et al. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol 2007;157:474-481.
- Ferrer L, Favera I, Silbermayr K. Immunology and pathogenesis of canine demodecosis. Vet Dermatol 2014;25:427-e65.
- Dirshka T, Tronnier H, Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Dr J Dermatol 2004;150:1136-1141.
- Roberts JO, Ward CM. Rhinophyma.J Royal Soc Med 1985;78:678-681.
- Browning DJ, Proia AD. Ocular rosacea. Surv Ophthalmol 1986;31:145-158.
- Rallis E, Korfitis C. Isotretinoin for the treatment of granulomatous rosacea: Case report and review of the literature. J Cutan Med Surg 2012;16:438-441.
- Farris P. Idebenone, green tea, and coffeeberry extract: New and innovative antioxidants. Dermatol Ther 2007;20:322-329.
- DelRosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, Part 1: A status report on the disease state, general measures, and adjunctive skin care. Cutis 2013;92:234-240.
- Del Rosso JQ. Management of facial erythema of rosacea: What is the role of topical α-adrenergic receptor agonist therapy? J Am Acad Dermatol 2013;69:S44-S56.
- Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, Part 5: A Guide on the Management of Rosacea. Cutis 2014;93:134-138.
- Van Zuuren EJ, Kramer S, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev 2011;3:CD003262.
- Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, Part 3: A status report on systemic therapies. Cutis 2014;93:18-28.
- Gollnick H, Blume-Peytavi U, Szabo EL, et al. Systemic isotretinoin in the treatment of rosacea — doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges 2010;8:505-515.
- Tüzün Y, Wolf R, Kutlubay Z, et al. Rosacea and rhinophyma. Clin Dermatol 2014;32:35-46.
MONOGRAPH: Here's an in-depth guide for the primary care physician.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content